THLD MNTA AINV VHC RSO TORM DMND GMCR APKT AMSC
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
interesting..LJPC now up 75%..lets see how 8:30 cc goes, may provide some clarity .
u and bob are buying breakfast..tia
u bi-trader u.."not that there is anything wrong with that"
banking on both sides of the fence
GT Advanced Tech wins $336M deal to supply Malaysian facility
GT Advanced Technologies (GTAT) signs a $336M deal to supply Cosmos Chemicals Berhad with equipment and technology for a 25,0000 metric ton annual (MTA) polysilicon facility in Sarawak, Malaysia.
The size of the deal compares with the almost $300M in revenue that GT generated in 2013, although the time element for the order doesn't appear to have been provided.
It's also worth pointing out that Cosmos Chemicals Berhad needs to secure final financing for the project
LJPC cc 8:30..sell the news or rip higher? TBD
FTEK hovering mid 5s..-18%..thinking lower after open
URBN off a bit p/m..on watch for volume
and FCEL +20% now ..was initially lower after earnings last night..
apparently BTFD applies even to pos tickers,lol
PLUG 11.50..i am going to be sick
American Eagle Outfitters, Inc. beats by $0.01, misses on revenue
American Eagle Outfitters, Inc. (AEO): Q4 EPS of $0.27 beats by $0.01.
Revenue of $1.04B (-7.1% Y/Y) misses by $10M.
Solid quarter from Dick's Sporting Goods, guidance light
Dick's Sporting Goods (DKS) matches the estimate of analysts with its Q4 report, but takes its guidance to below what analysts forecast.
The company saw same store sales for Dick's rise increase 7.9% during the quarter, while comps at weather-stricken Golf Galaxy fell 11.7%.
E-commerce penetration was 12.2% of total sales in Q4.
Looking ahead, Dick's sees same-store sales growth of 3% to 4% in 2014. The outlook from the company also includes Q1 EPS of $0.51-$0.53 vs. $0.54 consensus and FY14 EPS of $3.03-$3.08 vs. $3.11 consensus.
DKS -2.5% premarket
yeah nice group, I just checked and see that my cheapie inventory is missing in action..lol
Myriad down 11% premarket
Shares of Myriad Genetics (MYGN) are poised for an opening gap down on probable profit-taking after its recent 96% run-up from the December 30 low of $20.02.
12 of 18 analysts rate the company Hold, one Sell and five Buy.
Consensus estimates for Q1 and 2014 are EPS $0.45/share on revenues of $172M and $2.16/share on revenues of $752M, respectively.
441 mutual funds have positions, up from 411 a year earlier
More on Myriad Genetics
Shares are also under pressure in response to yesterday's US court ruling denying Myriad's (MYGN) motion for a preliminary injunction again Ambry Genetics. The company is trying to prevent its rival from selling a cancer test that it believes infringes on some of its patents.
http://www.reuters.com/article/2014/03/11/myriadgenetics-lawsuit-idUSL3N0M832F20140311?feedType=RSS&feedName=governmentFilingsNews
Myriad down 11% premarket
Shares of Myriad Genetics (MYGN) are poised for an opening gap down on probable profit-taking after its recent 96% run-up from the December 30 low of $20.02.
12 of 18 analysts rate the company Hold, one Sell and five Buy.
Consensus estimates for Q1 and 2014 are EPS $0.45/share on revenues of $172M and $2.16/share on revenues of $752M, respectively.
441 mutual funds have positions, up from 411 a year earlier
J.C. Penney on a rush after lively Citigroup upgrade
J.C. Penney (JCP) is on the move in early trading after Citigroup upgrades the stock to a Buy rating and raises its price target to $11.
Citi thinks the company can return to positive comps as the focus turns to the home department and kids departments.
What to watch: A return by J.C. Penney to seeing its sales mix of private brands return to historic norms (50% vs. 30% under Ron Johnson) could also do wonders for profitability.
JCP +8.1% premarket
waaaaaaaaaaaaaaaa..J.C. Penney on a rush after lively Citigroup upgrade
J.C. Penney (JCP) is on the move in early trading after Citigroup upgrades the stock to a Buy rating and raises its price target to $11.
Citi thinks the company can return to positive comps as the focus turns to the home department and kids departments.
What to watch: A return by J.C. Penney to seeing its sales mix of private brands return to historic norms (50% vs. 30% under Ron Johnson) could also do wonders for profitability.
JCP +8.1% premarket
Herbalife down 5% premarket
Shares of Herbalife (HLF) are poised for an opening gap down as investors absorb the latest information on its tussle with short seller Bill Ackman.
Ackman's Pershing Square hedge fund schedules a conference call today at 2 PM EDT to report on HLF's operations in China
Herbalife down 5% premarket
Shares of Herbalife (HLF) are poised for an opening gap down as investors absorb the latest information on its tussle with short seller Bill Ackman.
Ackman's Pershing Square hedge fund schedules a conference call today at 2 PM EDT to report on HLF's operations in China
Gov't backs down over limiting Medicare coverage for some drugs
The White House has dropped a proposal to permit insurers to limit Medicare coverage for certain types of pharmaceuticals, including drugs for depression and schizophrenia.
Medicare argued that the measure would have saved money, but the Administration ran into trouble with patients, drug firms and members of Congress from both parties.
Health insurers: AET, HNT, HUM, UNH, WLP, MOH.
ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS
http://www.nytimes.com/2014/03/11/us/politics/white-house-withdraws-plan-allowing-limits-to-medicare-coverage-for-some-drugs.html?partner=rss&emc=rss&_r=0
fwiw there are some raising flags already, could be answered by 8:30 cc or the cc could bring out the bears..hard to tell
https://twitter.com/adamfeuerstein/status/443126117713457152/photo/1
Virtu files for Nasdaq IPO
Virtu Financial has submitted an application for an IPO on Nasdaq, where it intends to trade under the symbol "VIRT."
The high-speed trading firm filed to raise $100M as a placeholder to calculate fees, although Bloomberg reports that the company hopes to draw in $250M at a valuation of up to $3B.
Virtu has only suffered one losing trading day in five years, and last year, net income more than doubled to $182.2M as revenue climbed 8% to $664.5M.
However, Virtu disclosed that the Commodity Futures Trading Commission is investigating the firm's "participation in certain incentive programs offered by exchanges or venues" from July 2011 to November 2013.
Crimea assembly votes to declare independence
Crimea's parliament has voted to declare independence from Ukraine ahead of a referendum this weekend in which the region's citizens will decide whether to join Russia.
Ukraine's parliament has said it will dissolve the Crimean assembly if it doesn't drop the referendum by tomorrow, although how much power Ukraine has in the province is looking rather questionable.
In other developments" Russia and the U.S. have declined to take part in new talks on the crisis; Ukraine is testing its military's combat readiness and may mobilize 20,000 people; a pro-Russian force opened fire when capturing a Ukrainian military base in Crimea yesterday; and NATO is carrying out reconnaissance flights over its eastern frontier.
In the U.S., the Senate is preparing an aid package for Ukraine that would include IMF funding.
Bayer drug fails Phase 3 trial.Bayer's (BAYRY) cancer drug Nexavar (sorafenib) fails to meet its primary endpoint of improving recurrence-free survival.
The target patient group is liver cancer patients who had no detectable disease after surgery.
The company states that it remains committed to exploring the full potential of the drug in all stages of liver cancer
http://www.reuters.com/article/2014/03/11/us-bayer-nexavar-idUSBREA2A0BN20140311
U.K.'s Lombard looks to join U.S. biotech party
Lombard Medical Technologies plans to delist in London and carry out an $80M IPO on Nasdaq, where it intends to trade under the ticker symbol "EVAR."
Lombard has yet to decide how many shares it will offer, nor at what price.
The U.K. medical-devices company, which focus on the repair of aneurysms, intends to use the proceeds from the offering to increase its U.S. sales force and to develop products.
http://online.wsj.com/article/PR-CO-20140311-902096.html
DSS..looks like could be nice runner tomorrow
Yup..bounced a buck..lol
LJPC $2 dip off 18.60 a/h high..cc 8:30am
LJPC..will I regret not smacking 16.30s? Lol
Wish I had hit it at 13..oopsie..let's see a.m.
TSLA ain't Ford either..bios all about hopium and potential market if drug succeeds..
Maybe..it has more than doubled near term..some profit taking expected..I believe one analyst put $27 target last month..no doublt a few more will jump on bandwagon tomorrow
POWR up 12% a/h..low vol
Probably Z getting a starter..lol
Klarman raises alarm over asset prices, cites tech “nosebleed valuations”
Seth Klarman is warning of an impending asset price bubble, calling out "nosebleed valuations” in high-flying stocks such as Netflix (NFLX) and Tesla (TSLA) and warning of the potential for a brutal correction across financial markets.“Any year in which the S&P 500 jumps 32% and the Nasdaq 40% while corporate earnings barely increase should be a cause for concern, not for further exuberance," the Baupost Group head wrote in a letter to clients."There is a growing gap between the financial markets and the real economy... and the overall picture is one of growing risk and inadequate potential return almost everywhere one looks."In a semi-rebuttal, Vanguard's Jack Bogle agrees stocks are in "risky territory" but says investors shouldn't be trying to time the market in any case, and the problem with selling stocks based on such a prediction is you won't know when to re-enter: "Will [Klarman] call you and tell you when it's time to get back in?"
Let's see how 8:30am cc goes..and if analysts get all giddy
Nah..stop beating yourself and redirect that energy to the next pos that will pull a lazarus
Lmao..could be
Document Security +6.4% AH on new lawsuit filings
Document Security Systems (DSS) is suing Samsung, TSMC, and NEC in the Eastern District of Texas for allegedly infringing patents related to chip manufacturing. (PR)DSS says it bought the patents in question in 2013 to support hardware/peripherals development, including for devices using its AuthentiGuard anti-counterfeiting tech.
FCEL reversed..now up 9%,.lol
U short a chit load over 18??